Please wait a minute...
浙江大学学报（医学版）
J Zhejiang Univ (Med Sci)  2019, Vol. 48 Issue (2): 142-147    DOI: 10.3785/j.issn.1008-9292.2019.04.04
    
Progress on medical treatment in the management of adenomyosis
Baboo Kalianee Devi(),CHEN Zhengyun,ZHANG Xinmei*()
Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Download: HTML( 12 )   PDF(908KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Drug therapy plays an important role in alleviating the symptoms related to adenomyosis, improving the curative effect of surgery, delaying the progress of disease and promoting assisted reproduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice to control pain associated with adenomyosis, and are the only choice for patients with recent fertility requirements; steroid hormones, gonadotropin releasing hormone agonists and mifepristone can effectively relieve pain and control uterine bleeding, among which oral contraceptives, levonorgestrel-releasing intranterine system (Mirena) and dienogest are more effective and commonly used in clinic. Drug selection should be based on patient's age, symptoms, uterine size, fertility requirements and economical conditions. At present, there is no specific drug for adenomyosis, and symptoms are easy to recur after drug withdrawal, so the long-term drug use needs further study.

Key words： Adenomyosis      Drug therapy      Review     
Received: 26 January 2019      Published: 24 July 2019
CLC:  R711.74  
Corresponding Authors: ZHANG Xinmei     E-mail: 21618649@zju.edu.cn;zhangxinm@zju.edu.cn
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Baboo Kalianee Devi
CHEN Zhengyun
ZHANG Xinmei
Cite this article:

Baboo Kalianee Devi,CHEN Zhengyun,ZHANG Xinmei. Progress on medical treatment in the management of adenomyosis. J Zhejiang Univ (Med Sci), 2019, 48(2): 142-147.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2019.04.04     OR     http://www.zjujournals.com/med/Y2019/V48/I2/142


子宫腺肌病患者药物治疗进展

药物治疗在缓解子宫腺肌病患者相关症状、提高手术疗效、延缓疾病进展和促进辅助生育方面具有重要的作用。非甾体抗炎药是控制子宫腺肌病相关疼痛的首选药物，是近期有生育要求患者的唯一选择；甾体激素、促性腺激素释放激素激动剂和米非司酮等药物可有效减轻疼痛和控制子宫出血，其中以口服避孕药、左炔诺孕酮宫内节育系统（曼月乐）和地诺孕素等甾体激素的疗效更确切。目前尚无用于子宫腺肌病的特效药物，应根据患者的年龄、症状、子宫大小、生育要求和经济条件等情况选择性应用，但停药后症状易复发。因此，子宫腺肌病患者药物长期应用有待进一步研究。


关键词： 子宫腺肌病,  药物疗法,  综述 
[1]   MARJORIBANKS J , AYELEKE R O , FARQUHAR C et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea[J]. Cochrane Database Syst Rev, 2015, (7): CD001751
[2]   LETHABY A , AUGOOD C , DUCKITT K et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding[J]. Cochrane Database Syst Rev, 2007, (4): CD000400
[3]   ITAM S P, AYENSU-COKER L, SANCHEZ J, et al. Adenomyosis in the adolescent population: a case report and review of the literature[J/OL]. J Pediatr Adolesc Gynecol, 2009, 22(5): e146-e147.
[4]   SCHAFER A I . Effects of nonsteroidal anti-inflammatory therapy on platelets[J]. Am J Med, 1999, 106 (5B): 25S- 36S
[5]   HAWKEY C J . COX-2 inhibitors[J]. Lancet, 1999, 353 (9149): 307- 314
doi: 10.1016/S0140-6736(98)12154-2
[6]   VERCELLINI P , VIGANò P , SOMIGLIANA E et al. Endometriosis:pathogenesis and treatment[J]. Nat Rev Endocrinol, 2014, 10 (5): 261- 275
doi: 10.1038/nrendo.2013.255
[7]   TSUI K H , LEE W L , CHEN C Y et al. Medical treatment for adenomyosis and/or adenomyoma[J]. Taiwan J Obstet Gynecol, 2014, 53 (4): 459- 465
doi: 10.1016/j.tjog.2014.04.024
[8]   SHAABAN O M , ALI M K , SABRA A M et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri:a randomized clinical trial[J]. Contraception, 2015, 92 (4): 301- 307
doi: 10.1016/j.contraception.2015.05.015
[9]   FERRERO S , REMORGIDA V , VENTURINI P L . Endometriosis[J]. BMJ Clin Evid, 2010, 2010 pii:0802
[10]   STEGEMAN B H , DE BASTOS M , ROSENDAAL F R et al. Different combined oral contraceptives and the risk of venous thrombosis:systematic review and network meta-analysis[J]. BMJ, 2013, 347 f5298
doi: 10.1136/bmj.f5298
[11]   RADZINSKY V E , KHAMOSHINA M B , NOSENKO E N et al. Treatment strategies for pelvic pain associated with adenomyosis[J]. Gynecol Endocrinol, 2016, 32 (sup2): 19- 22
doi: 10.1080/09513590.2016.1232673
[12]   SHENG J , ZHANG W Y , ZHANG J P et al. The LNG-IUS study on adenomyosis:a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis[J]. Contraception, 2009, 79 (3): 189- 193
doi: 10.1016/j.contraception.2008.11.004
[13]   李雷, 冷金花, 史精华 et al. LNG-IUS治疗子宫腺肌病相关经量过多的前瞻性研究[J]. 中华妇产科杂志, 2016, 51 (6): 424- 430
LI Lei , LENG Jinhua , SHI Jinhua et al. A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia[J]. Chinese Journal of Obstetrics and Gynecology, 2016, 51 (6): 424- 430
doi: 10.3760/cma.j.issn.0529-567x.2016.06.005
[14]   PETTA C A , FERRIANI R A , ABRAO M S et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis[J]. Hum Reprod, 2005, 20 (7): 1993- 1998
doi: 10.1093/humrep/deh869
[15]   KRIPLANI A , SINGH B M , LAL S et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia[J]. Int J Gynaecol Obstet, 2007, 97 (3): 190- 194
doi: 10.1016/j.ijgo.2007.01.009
[16]   LEE K H , KIM J K , LEE M A et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis[J]. Arch Gynecol Obstet, 2016, 294 (3): 561- 566
doi: 10.1007/s00404-016-4105-y
[17]   ZHANG P , SONG K , LI L et al. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis[J]. Med Princ Pract, 2013, 22 (5): 480- 483
doi: 10.1159/000351431
[18]   MAIA H , HADDAD C , CASOY J et al. Effect of a hormone-releasing intrauterine system (Mirena(?)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection[J]. Int J Womens Health, 2012, 4 175- 183
[19]   YU Q , ZHANG S , LI H et al. Dienogest for treatment of endometriosis in women:a 28-week, open-label, extension study[J]. J Womens Health(Larchmt), 2019, 28 (2): 170- 177
doi: 10.1089/jwh.2018.7084
[20]   FAWZY M , MESBAH Y . Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis:a prospective clinical trial[J]. Arch Gynecol Obstet, 2015, 292 (6): 1267- 1271
doi: 10.1007/s00404-015-3755-5
[21]   OSUGA Y , FUJIMOTO-OKABE H , HAGINO A . Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis:a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108 (4): 673- 678
doi: 10.1016/j.fertnstert.2017.07.021
[22]   NERⅡSHI K , HIRATA T , FUKUDA S et al. Long-term dienogest administration in patients with symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44 (8): 1439- 1444
doi: 10.1111/jog.2018.44.issue-8
[23]   MATSUSHIMA T , AKIRA S , FUKAMI T et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis[J]. Gynecol Minim Invasive Ther, 2018, 7 (3): 119- 123
doi: 10.4103/GMIT.GMIT_35_18
[24]   PONPUCKDEE J , TANEEPANICHSKUL S . The effects of implanon in the symptomatic treatment of endometriosis[J]. J Med Assoc Thai, 2005, 88 Suppl 2 S7- S10
[25]   WU J , HUANG Y , CHEN L et al. Treatment of adenomyosis with subcutaneous etonogestrel implants:a clinical observational study in 17 patients[J]. Med Sci Monit, 2018, 24 6085- 6092
doi: 10.12659/MSM.908979
[26]   NELSON J R , CORSON S L . Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist:a case report[J]. Fertil Steril, 1993, 59 (2): 441- 443
doi: 10.1016/S0015-0282(16)55704-5
[27]   KHAN K N , KITAJIMA M , HIRAKI K et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy[J]. Hum Reprod, 2010, 25 (3): 642- 653
doi: 10.1093/humrep/dep437
[28]   PIERCE S J , GAZVANI M R , FARQUHARSON R G . Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis:a randomized trial with a 6-year follow-up[J]. Fertil Steril, 2000, 74 (5): 964- 968
doi: 10.1016/S0015-0282(00)01537-5
[29]   TANG H , WU R , LI X et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage Ⅲ-Ⅳ endometriosis:Randomized controlled study[J]. J Obstet Gynaecol Res, 2017, 43 (10): 1550- 1554
doi: 10.1111/jog.2017.43.issue-10
[30]   孙长亮.超小剂量米非司酮治疗子宫腺肌病患者的疗效观察[J/CD].实用妇科内分泌杂志(电子版), 2016, 3(2): 116, 118.
SUN Changliang. Efficacy of low-dose mifepristone in treatment of adenomyosis[J/CD]. Journal of Practical Gynecologic Endocrinology(Electronic Edition), 2016, 3(2): 116, 118. (in Chinese)
[31]   NEWFIELD R S , SPITZ I M , ISACSON C et al. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia[J]. Clin Endocrinol(Oxf), 2001, 54 (3): 399- 404
doi: 10.1046/j.1365-2265.2001.01026.x
[32]   刘芳, 王承秀 . 孕三烯酮与米非司酮治疗子宫腺肌病80例临床效果分析[J]. 现代诊断与治疗, 2014, 25 (13): 2996- 2997
LIU Fang , WANG Chengxiu . Clinical analysis of gestrinone and mifepristone in treatment of 80 patients with adenomyosis[J]. Modern Diagnosis & Treatment, 2014, 25 (13): 2996- 2997
[1] YE Pingxian, YE Pingzhen, HE Jinping. Effect of trimetazidine on cardiac function and exercise tolerance in hypertension patients with diabetic[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 282-288.
[2] MA Jing, HE Wenlong, GAO Chongyang, YU Ruiyun, XUE Peng, NIU Yongchao. Glucosides of chaenomeles speciosa attenuate ischemia/reperfusion-induced brain injury by regulating NF-κB P65/TNF-α in mouse model[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 289-295.
[3] ZHU Ziling, TAN Jing, DENG Hong. Nucleus translocation of membrane/cytoplasm proteins in tumor cells[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 318-325.
[4] ZHANG Jianmin. Advances in surgical treatment of ischemic cerebrovascular disease[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 233-240.
[5] WU Yuxing, ZHANG Shihong, CHEN Zhong. The roles of habenula and related neural circuits in neuropsychiatric diseases[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 310-317.
[6] ZHANG Yunzhu, ZHU Chunpeng, LU Xinliang. Advances in serum biomarkers for early diagnosis of gastric cancer[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 326-333.
[7] ZHANG Xinmei,XU Ping. Stratified treatment and management of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 123-129.
[8] LOU Junyao,HUANG Xiufeng,ZHANG Lifeng,XU Ping,ZHANG Xinmei,CHEN Zhengyun. The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 136-141.
[9] WU Binbin,YANG Yi. Biomarkers of cardiac surgery-associated acute kidney injury: a narrative review[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 224-229.
[10] ZHANG Lifeng,YANG Hui,ZHANG Xinmei,CHEN Zhengyun. Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 130-135.
[11] YANG Kun,HU Xiaosheng. Research progress on miR-21 in heart diseases[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 214-218.
[12] XU Li,XU Ming,TONG Xiangmin. Effects of aerobic glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 219-223.
[13] ZHAO Shihao,ZHANG Xue,KE Yuehai. Progress on correlation between cell senescence and idiopathic pulmonary fibrosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 111-115.
[14] SONG Fangjun,GUO Hongtao. Progress on structural biology of voltage-gated ion channels[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 25-33.
[15] SHI Jing,FENG Jue. New inhibitors targeting bacterial RNA polymerase[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 44-49.